Innovations and know-how in exosome production suited for many clinical applicationsTORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies. NurExone’s Intellectual
Prof. Shulamit Levenberg from the Haifa Technion-Israel Institute of Technology is among the few Israeli women scientists who have invented the most innovative technologies and registered patents.
NurExone Biologic Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
An Organizational Perspective on the Process of Adopting Executable Exams acm.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acm.org Daily Mail and Mail on Sunday newspapers.